Related Experiment Video
Updated: Sep 17, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
CAR-T cell therapy for glioblastoma: insight from mathematical modeling
Magdalena Szafrańska-Łęczycka1, Zuzanna Szymańska2, Monika J Piotrowska3
1Doctoral School of Exact and Natural Sciences, University of Warsaw, Warsaw, Poland.
Introduction:
Glioblastoma is a rare, aggressive brain tumor marked by high therapeutic resistance, poor prognosis, and limited treatment options. Emerging immunotherapies, particularly Chimeric Antigen Receptor (CAR) T-cell therapy, offer promising alternatives to standard care. However, adapting CAR-T cell strategies from hematologic malignancies to solid tumors like glioblastoma presents substantial challenges.
Methods:
We extended existing mathematical models to investigate glioblastoma treatment dynamics with CAR-T cell therapy. Simulations were based on clinical trial-inspired scenarios targeting IL13Rα2, HER2, and EGFRvIII antigens, assessing both single-dose and cyclic dosing regimens. The models incorporated key biological processes, including tumor growth, CAR-T cell proliferation delays, and resistance mechanisms.
Results:
Cyclic CAR-T cell administration outperformed single-dose strategies in reducing tumor burden. Incorporating resistance and treatment delays into the models provided critical insights into relapse dynamics and therapeutic durability.
Discussion:
This study presents a comprehensive modeling framework for CAR-T cell therapy in glioblastoma, highlighting the importance of dosing regimens and resistance dynamics. The findings offer valuable guidance for optimizing therapeutic strategies to enhance patient outcomes.
Insights
Cyclic Chimeric Antigen Receptor (CAR) T-cell therapy shows greater efficacy than single-dose treatments for glioblastoma. Mathematical models reveal cyclic dosing improves tumor reduction and treatment durability, guiding future glioblastoma immunotherapy strategies.
Area of Science:
- Oncology
- Immunotherapy
- Mathematical Modeling
Background:
- Glioblastoma is an aggressive brain tumor with poor prognosis and limited treatment options.
- Chimeric Antigen Receptor (CAR) T-cell therapy is a promising immunotherapy, but faces challenges in solid tumors like glioblastoma.
Purpose of the Study:
- To develop and utilize mathematical models to investigate glioblastoma treatment dynamics with CAR T-cell therapy.
- To compare the efficacy of single-dose versus cyclic dosing regimens for CAR T-cell therapy in glioblastoma.
- To explore the impact of biological factors like proliferation delays and resistance mechanisms on treatment outcomes.
Main Methods:
- Extended existing mathematical models to simulate glioblastoma treatment scenarios.
- Incorporated key biological processes: tumor growth, CAR T-cell proliferation delays, and resistance.
- Simulated clinical trial-inspired scenarios targeting IL13Rα2, HER2, and EGFRvIII antigens.
Main Results:
- Cyclic CAR T-cell administration demonstrated superior tumor burden reduction compared to single-dose strategies.
- Model simulations provided insights into relapse dynamics and the importance of treatment durability.
- Resistance mechanisms and treatment delays significantly influenced therapeutic outcomes.
Conclusions:
- A comprehensive modeling framework was established for CAR T-cell therapy in glioblastoma.
- Dosing regimens and resistance dynamics are critical factors for optimizing glioblastoma immunotherapy.
- Findings offer guidance for enhancing patient outcomes in glioblastoma treatment.
More Related Videos
10:01Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014